Today (August 30), the 2020 (37th) National Pharmaceutical Industry Information Annual Conference & 2019 China's Top 100 Pharmaceutical Industry Enterprises Press Conference organized by China National Pharmaceutical Industry Information Center was held in Zhuhai, Guangdong, during which "2020 Best Industrial Enterprises in China's Pharmaceutical R&D Product Line" were grandly announced. Jiangsu Hansoh Pharmaceutical Group Co., Ltd. ("Hansoh Pharma" or "Company") was once again ranked second by virtue of its excellent R&D strength and innovative achievements, the fourth consecutive year of its ranking among top three on the list since 2017.
Hansoh Pharma's receipt of this honor despite the fierce competition not only highlights its brand strength in the pharmaceutical field, but also is an authoritative affirmation of its innovative R&D capability in the industry. As one of the most authoritative and representative industry lists in China, "2020 Best Industrial Enterprises in China's Pharmaceutical R&D Product Line" were reportedly selected by experts organized by China National Pharmaceutical Industry Information Center at two levels of drug and enterprise, from four aspects of innovation, development, leadership and scale, and in a fair, objective and authoritative perspective, aimed at tracking the R&D trends at home and abroad in real time and identifying the strongest voices in the domestic pharmaceutical R&D field.
Focus on innovation is the core driver behind Hansoh Pharma's development. In order to build an efficient and sustainable R&D innovation capability, Hansoh Pharma has established R&D centers in Shanghai and Lianyungang, continuously increased investment in R&D year by year, created a number of leading R&D platforms and mastered a batch of proprietary technologies. It has vigorously trained and engaged high-level technical talents, accelerated the cultivation of innovative talents, and formed a first-class R&D team led by high-end talents and master/doctoral degree holders. The Company has undertaken more than 40 national-level scientific research projects including 863 Program, "Major New Drug Innovation and Development" Science and Technology Special Project, and Torch Program; has won 2 second prizes in the National Scientific and Technological Progress Award and 1 gold medal in China Patent Award; and has been granted more than 300 invention patents at home and abroad on a cumulative basis.
As Hansoh Pharma continues to make strides in R&D, its innovation transformation has entered the harvest period. Up to June 2020, the Company has four Class 1 innovative drugs approved for marketing: Ameile (Ametinib Mesylate Tablets), Hansoh Xinfu (Flumatinib Mesylate Tablets), Fulaimei (Polyethylene Glycol Loxenatide Injection), and Mailingda (Morinidazole and Sodium Chloride Injection). As a leading innovation-driven pharmaceutical company in China, Hansoh Pharma focuses on the R&D of new products in the fields of central nervous system diseases, anti-tumor, anti-infection and diabetes, and currently has more than 100 projects under research, including 5 innovative drugs in clinical phase II and beyond.
Living up to its corporate mission to "create excellence in pharmaceuticals, enhance innovation in China", Hansoh Pharma will closely follow the pulse of health industry development, accelerate the pace of scientific and technological innovation, and contribute wisdom and strength to the leap-forward development of medical science and technology innovation and human health.
